ES2586328T3 - Factores predisponentes para el tratamiento del cáncer - Google Patents

Factores predisponentes para el tratamiento del cáncer Download PDF

Info

Publication number
ES2586328T3
ES2586328T3 ES12754124.1T ES12754124T ES2586328T3 ES 2586328 T3 ES2586328 T3 ES 2586328T3 ES 12754124 T ES12754124 T ES 12754124T ES 2586328 T3 ES2586328 T3 ES 2586328T3
Authority
ES
Spain
Prior art keywords
positive
rituximab
biomarkers
psmb1
cancer treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12754124.1T
Other languages
English (en)
Inventor
Deborah Ricci
Weimin Li
Erin Devay HENITZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Application granted granted Critical
Publication of ES2586328T3 publication Critical patent/ES2586328T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)

Abstract

Un método de predicción de la respuesta a un tratamiento del cáncer que comprende bortezomib y rituximab en un paciente con cáncer de linfoma no Hodgkin, que comprende: determinar el nivel o la cantidad de un primer factor predisponente en una muestra biológica de dicho paciente, en el que dicho primer factor predisponente es CD68 o el polimorfismo de PSMB1 (P11A); y determinar la presencia o cantidad de un segundo factor predisponente en dicho paciente; en el que CD68 bajo o la presencia del polimorfismo de PSMB1 (P11A) se correlaciona con al menos un resultado positivo, y la presencia, ausencia o cantidad de dicho segundo factor predisponente se correlaciona con al menos un resultado positivo.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
5
10
15
20
25
30
35
40
Ciento dos pares de biomarcadores tuvieron una p<0,05 de rangos logarítmicos. De estos, 97 pares tenían una frecuencia de >1 % en la población. Catorce pares mostraron, además, una mejora de PFS de ≥6 meses. En este análisis, se hicieron 1.140 comparaciones por pares (las covariables se aparearon con cada marcador individual para complementar los análisis). Después de la corrección de FDR, 1 par fue significativo (FDR = 0,051). Este par de biomarcadores identificó el 33 % de la población evaluable de biomarcadores con una ventaja de 7,5 meses de PFS cuando se trataron con Vc-R en comparación con rituximab solo (Tabla 4) y una tendencia a una mejor OS (p = 0,055, HR: 0,426 [0,174,1,046], Este par se compone de PSMB1 P11A (heterocigoto C/G) y baja expresión de CD68 definido como 0-50 células teñidas positivamente. A continuación, este par se mencionará como el subgrupo de biomarcadores positivos. El subgrupo de biomarcadores negativos no tiene este par de biomarcadores y tiene un diferente genotipo de PSMB1 y nivel de expresión de CD68.
Tabla 4: Comparación de la PFS y la OS de la población de biomarcadores positivos con la población de biomarcadores negativos
Biomarcador positivo (N=118)
Biomarcador negaitivo (N=238) Total (N=356)
Vc-R
Rituximab Vc-R Rituximab Vc-R Rituximab
N
57 61 118 120 175 181
Mediana (meses
16.6 9.1 12.5 12.5 13.6 11.3
PFS
95% CI (0.26-0.639) (0.759-1.425) (0.621-1.032)
Valor-p
0.0001 0.8097 0.0855
HR
0.407 1.04 0.801
Vc-R
Rituximab Vc-R Rituximab Vc-R Rituximab
N
57 61 118 120 175 181
Mediana (meses
NA NA NA NA NA NA
OS
95% CI (0.174-1.046) (0.617-1.658) (0.527-1.239)
Valor-p
0.0550 0.9645 0.3270
HR
0.426 1.011 0.808
Biomarcador positivo = PSMB heterocigoto P11a y CD68 "baja" par biomarcador, biomarcador negativo = todos los sujetos sin este par, Vc-R = Bortezomib + Rituximab, PFS = supervivencia libre de progresión, OS = supervivencia global, IC = confianza intervalo, HR = cociente de riesgos instantáneos
De manera importante, el subgrupo de biomarcadores positivos (heterocigoto de PSMB1 P11A y baja expresión de CD68) tuvo, además, una velocidad de respuesta total significativamente mejor del 73,7 % para los tratados con Vc-R en comparación con el 47,5 % con R solo (p=0,0077), y un tiempo más largo hasta el siguiente tratamiento (p = 0,0013) y duración del intervalo sin tratamiento (p=0,0017).
Se observaron perfiles AE similares en las poblaciones de biomarcadores positivos y biomarcadores negativos. Se observó una exposición al tratamiento similar en las poblaciones de biomarcadores positivos y de biomarcadores negativos. Los sujetos tratados con rituximab en la población de biomarcadores positivos tuvieron una mediana de la dosis de 2941 mg/m2 en comparación con 2940 mg/m2 en la población de biomarcadores negativos. Los sujetos tratados con Vc-R en la población de biomarcadores positivos tuvieron una mediana de la dosis de 31,1 mg/m2 en comparación con 30 mg/m2 en la población de biomarcadores negativos. Además el número total de dosis, la duración de la exposición, la intensidad de la dosis, la intensidad relativa de dosis y el número máximo de ciclos recibidos mostraron diferencias muy similares.
Los sujetos tratados con bortezomib + rituximab mantuvieron PFS más larga cuando el biomarcador fue positivo y se estratificaron por cualquiera de la puntuación FLIPI, por la carga tumoral, por la puntuación de Ann Arbor, por la edad, por la región, por el sexo y por la raza. En los pacientes con mayor riesgo y mal pronóstico, por ejemplo, alta carga tumoral, medio o alto FLIPI, mayores de 65 años, o con tratamiento previo con rituximab, se observaron mejoras mayores de PFS en pacientes cuando el biomarcador es positivo en comparación a cuando el biomarcador es negativo. La PFS más larga se mantuvo independientemente del tiempo a partir del último tratamiento o el número de tratamientos previos por rituximab previo o el número de tratamientos con rituximab menores o iguales a
2.
Los sujetos tratados con bortezomib + rituximab mantuvieron una supervivencia global más larga cuando el biomarcador fue positivo y se estratificaron por la puntuación de FLIPI, por la carga tumoral, por la puntuación de Ann Arbor, por la edad, por la región, por el sexo y por la raza. Los sujetos tratados con Velcade + rituximab mantuvieron una PFS más larga cuando fueron positivos para CD68 bajo (0-50) y se estratificaron por cualquiera de la puntuación FLIPI, por la carga tumoral, por la puntuación de Ann Arbor, por la edad, por la región, por el sexo y
12
imagen11
imagen12
Tabla 6. Pares marcadores significativos
Marcador A
Marcador B PFS Vc+R vs. R media meses N Vc+R vs. R Logrank Valor-p FDR
PSMB5/R24C C/T
P65 Intensidad de señal citoplasmica <=1+ 27 mo vs. 10.4 mo 16.6 mo mejora 5 vs. 7 0.0439 0.489
PSMB1/P11A C/G
20S % SEÑALCITOPLASMICA POSTIVA: >90 18.9 mo vs. 9.5 mo 9.4 mejora 50 vs50 0.0145 0.447
PSMB1/P11A C/G
CD68 Positivo folicular 0-50 16.6 mo vs. 9.1 mo 7.5 mejora 57 vs61 0.0001 0.051
PSMB1/P11A C/G
CD68 Positivo peri – folicular: >50 16.6 mo vs. 9.2 mo 7.4 Mo mejora 24 vs28 0.0365 0.471
PSMB9/R60H G/G
P65 % TINCIÓN NUCLEAR: >0 16.2 mo vs. 9.5 mo 6.7 mejora 35 vs28 0.0303 0.455
PSMB5/R24C C/T
CD68 Positivo folicular 0-50 13.7 mo vs. 7.2 mo 6.5 mo mejora 18 vs21 0.0220 0.447
HI Tumor BD NO
CD68 Positivo global 0-50 22.8 mo vs. 16 mo 6.8 mo mejora 64 vs68 0.0177 0.447
HI Tumor BD NO
CD68 Positivo folicular 0-50 20.5 mo vs. 13.8 mo 6.7 mo mejora 64 vs66 0.0310 0.455
Prior RX: 1
CD68 Positivo folicular 0-50 18.2 mo vs. 9.3 mo 8.9 mo mejora 63 vs69 0.0129 0.447
PSMB1/P11A C/G
Tiempo desde último Rx: > 1 año 18.2 mo vs. 10.7 mo 7.5 mo mejora 72 vs74 0.0198 0.447
Prior Ritutux NO
CD68 Positivo folicular 0-50 15.9 mo vs. 9.2 mo 6.7 mo mejora 73 vs88 0.0066 0.437
PSMB1/P11A C/G
Grupo edad <=65 15.3 mo vs. 9.2 mo 6.1 mo mejora 86 vs96 0.0071 0.437
Sexo Masculino
20S % TINCION NUCLEAR: >20 13.7 mo vs. 7.7 mo 6 mo mejora 63 vs48 0.0050 0.437
Grupo carrera OTRO
20S % TINCION NUCLEAR: >20 11.4 mo vs. 3.8 mo 7.6 mo mejora 11 vs 7 0.0320 0.455
PSMB1/P11A C/G
PSMB5/R24C C/T 13.7 mo vs. 7.8 mo 5.9 mo mejora 7 vs. 7 0.0221 0.4468
Tabla 7 Pares marcadores significativos
Combinación
PFS Vc-R vs. R media meses Logrank Valor-p
P65 Señal Citoplasmica >90% & 1
23.6 vs. 10.6 mo (13mo) 0.0132
tratamiento anterior*
16 vs. 8.9 mo (7.1mo) n.s.
CD68 Pos Folico (0-50) & P11A[C/G]**
14.2 vs 8.5 mo (5.7 mo) 0.0025
14.4 vs 9.2 mo (5.2 mo)
n.s.
10 Arif A (2009), Jamal S, Mushtaq S, Ahmed S, Mubarik A. Frequency of bcl-2 gene rearrangement in B-Cell NonHodgkin’s lymphoma. Asian Pacific J Cancer Prev 2009; 10(2): 237-240.
Binstadt BA (2003), Geha RS, Bonilla FA. IgG Fc receptor polymorphisms in human disease: Implications for intravenous immunoglobulin therapy. J Allergy Clin Immunol 2003; 111(4): 697-703.
15 Cartron G (2002), Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRllla gene. Blood 2002; 99(3): 754-758.
20 Chen P (1996), Hochstrasser M. Autocatalytic subunit processing couples active site formation in the 20S proteasome to completion of assembly. Cell 1996; 86: 961-972.
Chen S (2010), Blank JL, Peters T, Liu XJ, Rappoli DM, Pickard MD, Menon S, Driscoll DL, Lingaraj T, Burkhardt AL,
15
imagen13
imagen14
imagen15
imagen16
Apéndice 2, Tabla 2.2: OS variante genética de la línea germinal nd por covariable, revisión IRC (significativa [p≤0,05], frecuencia de ≥10 % o superior)
Vc-R Marcador: Subgrupo N
Marcador: Nivel Subgrupo HR (Escala log) R Media
Media total
3Lineas prioritarias de la terapita
Puntuación intermedia FLIPI
Ann Arbor Etapa IV
5
Apéndice 2, Tabla 2.3: OS por mutación somática y por covariable, revisión IRC (significativa [p≤0,05], frecuencia de ≥10 % o superior)
10 Marcador: Nivel Subgrupo HR ( Escala log) R Media Vc-R Media
2Lineas prioritarias de la terapia
No carga alta de tumor
15
Carga alta de tumor
Puntuacion FLIPI alta
Terapia no prior 20 Rituximab
Resto del Mundo
>65 Años de edad
25
Femenino
Masculino
30 Masculino
Masculino
Ann Arbor Etapa IV
35
40
45
50
20
imagen17
imagen18
imagen19
imagen20
imagen21
imagen22
imagen23
imagen24
imagen25
imagen26
imagen27
imagen28
imagen29
imagen30
imagen31
imagen32
imagen33
imagen34
imagen35
imagen36
imagen37
imagen38
imagen39
imagen40
imagen41
imagen42
imagen43
imagen44
imagen45
imagen46
imagen47
imagen48
imagen49
imagen50
imagen51
imagen52
imagen53
imagen54
imagen55
imagen56
imagen57
imagen58
imagen59
imagen60
imagen61
imagen62
imagen63
imagen64
imagen65
imagen66
imagen67
imagen68
imagen69
imagen70
imagen71
imagen72
imagen73
imagen74
imagen75
imagen76
imagen77
imagen78
imagen79
imagen80
imagen81
imagen82
imagen83
imagen84
imagen85
imagen86
imagen87
imagen88
imagen89
imagen90
imagen91
imagen92
imagen93

Claims (1)

  1. imagen1
ES12754124.1T 2011-08-11 2012-08-08 Factores predisponentes para el tratamiento del cáncer Active ES2586328T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161522596P 2011-08-11 2011-08-11
US201161522596P 2011-08-11
US201161560555P 2011-11-16 2011-11-16
US201161560555P 2011-11-16
PCT/US2012/049941 WO2013022935A1 (en) 2011-08-11 2012-08-08 Predictors for cancer treatment

Publications (1)

Publication Number Publication Date
ES2586328T3 true ES2586328T3 (es) 2016-10-13

Family

ID=47668910

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12754124.1T Active ES2586328T3 (es) 2011-08-11 2012-08-08 Factores predisponentes para el tratamiento del cáncer

Country Status (19)

Country Link
US (1) US9322066B2 (es)
EP (1) EP2742356B1 (es)
JP (1) JP6002222B2 (es)
CN (1) CN103930785B (es)
AU (1) AU2012294493B2 (es)
CA (1) CA2844825A1 (es)
CY (1) CY1117838T1 (es)
DK (1) DK2742356T3 (es)
ES (1) ES2586328T3 (es)
HR (1) HRP20160851T1 (es)
HU (1) HUE029295T2 (es)
MX (1) MX357429B (es)
PL (1) PL2742356T3 (es)
PT (1) PT2742356E (es)
RS (1) RS55053B1 (es)
RU (1) RU2600026C2 (es)
SI (1) SI2742356T1 (es)
SM (1) SMT201600235B (es)
WO (1) WO2013022935A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10795879B2 (en) 2012-06-22 2020-10-06 Iqvia Inc. Methods and systems for predictive clinical planning and design
US20130346111A1 (en) * 2012-06-22 2013-12-26 Quintiles Transnational Corporation Systems and Methods for Subject Identification (ID) Modeling
EP3164506A4 (en) * 2014-07-01 2018-02-28 Mayo Foundation for Medical Education and Research Methods and materials for identifying and treating mammals resistant to proteasome inhibitor treatments
KR102422975B1 (ko) * 2014-09-10 2022-07-20 리텐스 오토모티브 파트너쉽 비틀림 스프링력을 이용하는 비례 감쇠형 동력 전달 장치
CN109475600A (zh) * 2016-06-17 2019-03-15 瓦里安医疗系统公司 免疫调节剂与辐射治疗组合
CN106874710A (zh) * 2016-12-29 2017-06-20 安诺优达基因科技(北京)有限公司 一种用于利用肿瘤ffpe样本检测体细胞突变的装置
CN106845153A (zh) * 2016-12-29 2017-06-13 安诺优达基因科技(北京)有限公司 一种用于利用循环肿瘤dna样本检测体细胞突变的装置
CN110462239B (zh) 2017-03-28 2022-05-10 利滕斯汽车合伙公司 在弹簧止挡部与阻尼构件之间具有选定的角度的隔离装置
EP3705584A1 (en) 2019-03-05 2020-09-09 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Method of identifying patients with bortezomib resistant multiple myeloma and other blood diseases

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5693617A (en) 1994-03-15 1997-12-02 Proscript, Inc. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US6335358B1 (en) 1995-04-12 2002-01-01 President And Fellows Of Harvard College Lactacystin analogs
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
US6096778A (en) 1997-10-07 2000-08-01 Cephalon, Inc. α-ketoamide multicatalytic protease inhibitors
US6075150A (en) 1998-01-26 2000-06-13 Cv Therapeutics, Inc. α-ketoamide inhibitors of 20S proteasome
US6831099B1 (en) 1999-05-12 2004-12-14 Yale University Enzyme inhibition
PT3078667T (pt) 2001-01-25 2018-12-28 The United States Of America Represented By The Sec Dep Of Health And Human Services Formulação de compostos de ácido borónico
EP1581629B1 (en) * 2002-12-06 2015-04-01 Millennium Pharmaceuticals, Inc. Methods for the identification, assessment, and treatment of patients with proteasome inhibition therapy
CN100366636C (zh) * 2004-12-08 2008-02-06 中国农业科学院畜牧研究所 猪生产及免疫性状相关蛋白，它的编码基因与应用
KR100653990B1 (ko) 2004-12-29 2006-12-05 주식회사 하이닉스반도체 포토마스크 데이터베이스 패턴의 불량 검사 방법
AU2006254834B2 (en) 2005-06-08 2012-09-20 Millennium Pharmaceuticals, Inc. Treatment of patients with cancer therapy
AU2007284724B2 (en) 2006-08-10 2014-03-13 Millennium Pharmaceuticals, Inc. For the identification, assessment, and treatment of patients with cancer therapy
US20100086922A1 (en) 2008-05-30 2010-04-08 Millennium Pharmaceuticals, Inc. Assessment of chromosomal alterations to predict clinical outcome of bortezomib treatment

Also Published As

Publication number Publication date
AU2012294493A1 (en) 2014-02-20
WO2013022935A1 (en) 2013-02-14
RU2014108986A (ru) 2015-09-20
CY1117838T1 (el) 2017-05-17
HRP20160851T1 (hr) 2016-09-23
US9322066B2 (en) 2016-04-26
RU2600026C2 (ru) 2016-10-20
JP2014524571A (ja) 2014-09-22
MX2014001619A (es) 2014-11-10
SI2742356T1 (sl) 2016-06-30
EP2742356B1 (en) 2016-04-27
PT2742356E (pt) 2016-06-06
HK1199094A1 (en) 2015-06-19
HK1199097A1 (zh) 2015-06-19
SMT201600235B (it) 2016-08-31
JP6002222B2 (ja) 2016-10-05
RS55053B1 (sr) 2016-12-30
PL2742356T3 (pl) 2016-11-30
EP2742356A1 (en) 2014-06-18
HUE029295T2 (en) 2017-02-28
CA2844825A1 (en) 2013-02-14
MX357429B (es) 2018-07-09
AU2012294493B2 (en) 2017-02-23
DK2742356T3 (en) 2016-05-23
CN103930785B (zh) 2016-05-18
US20130216524A1 (en) 2013-08-22
CN103930785A (zh) 2014-07-16

Similar Documents

Publication Publication Date Title
Saddawi-Konefka et al. Lymphatic-preserving treatment sequencing with immune checkpoint inhibition unleashes cDC1-dependent antitumor immunity in HNSCC
Esteban-Fabró et al. Cabozantinib enhances anti-PD1 activity and elicits a neutrophil-based immune response in hepatocellular carcinoma
Thijssen et al. Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia
Chen et al. Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma
EP3458604B1 (en) Method for determining sensitivity to a cdk4/6 inhibitor
Grever et al. Hairy cell leukemia: update on molecular profiling and therapeutic advances
Olive et al. Residual γH2AX after irradiation of human lymphocytes and monocytes in vitro and its relation to late effects after prostate brachytherapy
Seo et al. Clinical features and outcomes in patients with human immunodeficiency virus-negative, multicentric Castleman's disease: a single medical center experience
US20210395722A1 (en) TTF Generated Proliferation of Cytotoxic T Cells to Create a Specific Pro-Inflammatory Response
US20250201339A1 (en) Use of combined cd274 copy number changes and tmb to predict response to immunotherapies
WO2019178283A1 (en) Methods and compositions for treating and prognosing colorectal cancer
van Hooij et al. BCG-induced immunity profiles in household contacts of leprosy patients differentiate between protection and disease
US10220016B2 (en) Methods and materials for assessing chemotherapy responsiveness and treating cancer
Ohmoto et al. Clinical features and treatment strategies for post-transplant and iatrogenic immunodeficiency-associated lymphoproliferative disorders
JP2017523130A (ja) 視神経脊髄炎の治療に対する高可溶性アクアポリン−４細胞外ループペプチド免疫化
ES2351456A1 (es) Metodo in vitro para el pronostico o prediccion de la respuesta por parte de pacientes con artritis reumatoide al tratamiento con agentes que reconocen el receptor de membrana cd20 de los linfocitos b.
WO2022272309A1 (en) Methods of using somatic hla-i loh to predict response of immune checkpoint inhibitor-treated patients with lung cancer
CN119287012A (zh) 一种治疗靶点在抑制肾癌细胞转移和增殖产品上的应用
JP2023510113A (ja) 神経膠芽腫を処置するための方法
Mao et al. PD-1 blockade-driven anti-tumor CD8+ T cell immunity requires XCR1+ dendritic cells
US20220003770A1 (en) Classification and Treatment of Gastric Cancer
Vagts et al. Trimer IgG and neutralising antibody response to COVID-19 mRNA vaccination in individuals with sarcoidosis
CN101492725A (zh) Magea4基因的应用
US20240426810A1 (en) Anti-pd1 therapy based on response to ifn-i stimulation
Li et al. Gemcitabine plus nivolumab with carboplatin or oxaliplatin in cisplatin-ineligible patients with metastatic urothelial carcinoma: a randomized phase II trial